KR870003101A - 2-oxo-1-[[(substituted sulfonyl) amino] carbonyl] azetidine - Google Patents

2-oxo-1-[[(substituted sulfonyl) amino] carbonyl] azetidine Download PDF

Info

Publication number
KR870003101A
KR870003101A KR1019860008067A KR860008067A KR870003101A KR 870003101 A KR870003101 A KR 870003101A KR 1019860008067 A KR1019860008067 A KR 1019860008067A KR 860008067 A KR860008067 A KR 860008067A KR 870003101 A KR870003101 A KR 870003101A
Authority
KR
South Korea
Prior art keywords
amino
compound
oxo
carbonyl
thiazolyl
Prior art date
Application number
KR1019860008067A
Other languages
Korean (ko)
Other versions
KR900001013B1 (en
Inventor
브로이어 헤르만
디. 트로이너 우베
에이취.코스터 윌리암
잘러 로버트
Original Assignee
니콜라스 피. 말라테스티니크
이이.아르. 스퀴부 앤드 산즈 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피. 말라테스티니크, 이이.아르. 스퀴부 앤드 산즈 인코오포레이티드 filed Critical 니콜라스 피. 말라테스티니크
Publication of KR870003101A publication Critical patent/KR870003101A/en
Application granted granted Critical
Publication of KR900001013B1 publication Critical patent/KR900001013B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

내용 없음No content

Description

2-옥소-1-[[(치환된 술포닐)아미노]카르보닐]아제티딘2-oxo-1-[[(substituted sulfonyl) amino] carbonyl] azetidine

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (27)

하기 일반식을 갖는 화합물 또는 그의 제약상 허용되는 염.Compounds having the following general formula or pharmaceutically acceptable salts thereof. 이고,ego, R1은 카르복실산에서 유도된 아실기이고,R 1 is an acyl group derived from carboxylic acid, R2및 R3는 서로 동일하거나 상이한 것으로서, 각각 수소, 알킬, 알케닐, 알키닐, 시클로알킬, 페닐, 치환된 페닐 또는 4원, 5원, 6원 또는 7원 헤테로싸이클이거나 또는 R2및 R3중의 하나는 수소이고 다른 하나는 아직도, 할로메틸, 디할로메틸, 트리할로메틸, 알콕시카르보닐, 2-페닐에테닐, 2-페닐에티닐, 카르복실,R 2 and R 3 are the same or different from each other and are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, substituted phenyl or a 4, 5, 6 or 7 membered heterocycle or R 2 and One of R 3 is hydrogen and the other is still halomethyl, dihalomethyl, trihalomethyl, alkoxycarbonyl, 2-phenylethenyl, 2-phenylethynyl, carboxyl, X1은 아지도, 아미노, 히드록시, 카르복실, 알콕시카르보닐, 알카노일아미노, 페닐카르보닐아미노, (치환된 페닐)카르보닐아미노, 알킬술포닐옥시, 페닐술포닐옥시, (치환된 페닐)술포닐옥시, 페닐, 치환된 페닐, 시아노, X 1 is azido, amino, hydroxy, carboxyl, alkoxycarbonyl, alkanoylamino, phenylcarbonylamino, (substituted phenyl) carbonylamino, alkylsulfonyloxy, phenylsulfonyloxy, (substituted phenyl Sulfonyloxy, phenyl, substituted phenyl, cyano, X2는 알킬, 치환된 알킬, 페닐, 치환된 페닐, 페닐알킬, (치환된 페닐)알킬, 알카노일, 페닐알카노일, (치환된 페닐)알카노일, 페닐카르보닐, (치환된 페닐)카르보닐 또는 헤테로아릴카르보닐기이고,X 2 is alkyl, substituted alkyl, phenyl, substituted phenyl, phenylalkyl, (substituted phenyl) alkyl, alkanoyl, phenylalkanoyl, (substituted phenyl) alkanoyl, phenylcarbonyl, (substituted phenyl) car A carbonyl or heteroarylcarbonyl group, X3및 X4중의 하나는 수소이고, 다른 하나는 수소 또는 알킬기이거나 또는 X3및 X4는 그들이 결합한 탄소원자와 함께 시클로알킬기를 형성하고,One of X 3 and X 4 is hydrogen, the other is hydrogen or an alkyl group or X 3 and X 4 together with the carbon atom to which they are attached form a cycloalkyl group, X5는 프로밀, 알카노일, 페닐카르보닐, (치환된 페닐)카르보닐, 페닐알킬카르보닐, (치환된 페닐)알킬카르보닐, 카르복실, 알콕시카르보닐, 아미노카르보닐, (치환된 아미노)카르보닐 또는 시아노기이고,X 5 is propyl, alkanoyl, phenylcarbonyl, (substituted phenyl) carbonyl, phenylalkylcarbonyl, (substituted phenyl) alkylcarbonyl, carboxyl, alkoxycarbonyl, aminocarbonyl, (substituted amino Carbonyl or cyano group, X6및 X7은 서로 동일하거나 또는 상이한 것으로서, 각각 수소, 알킬, 페닐 또는 치환된 페닐이거나 또는 X6은 수소이고, X7은 아미노, 치환된 아미노, 알카노일아미노 또는 알콕시이거나 또는 X6및 X7은 그들이 결합한 질소원자와 함께 4원, 5원, 6원 또는 7원 헤테로싸이클을 형성하고,X 6 and X 7 are the same or different from each other and are each hydrogen, alkyl, phenyl or substituted phenyl or X 6 is hydrogen, X 7 is amino, substituted amino, alkanoylamino or alkoxy or X 6 and X 7 together with the nitrogen atom to which they are attached form a four, five, six or seven membered heterocycle, A는 -CH=CH-, -(CH2)m-, -((CH2)m-O-, -(CH2)m-NH- 또는 -CH2-S-CH2-(m은 0,1 또는 2임)이고,A is -CH = CH-,-(CH 2 ) m -,-((CH 2 ) m -O-,-(CH 2 ) m -NH- or -CH 2 -S-CH 2- (m is 0 , 1 or 2), A5는 단일 결합, -CH2-, -NH-CH2, -N=CH- 또는 A 5 is a single bond, -CH 2- , -NH-CH 2 , -N = CH- or A6는 단일 결합, -CH=CH- 또는 -(CH2)t-이고,A 6 is a single bond, -CH = CH- or-(CH 2 ) t- , 여기서 p는 0 또는 1이고,Where p is 0 or 1, y는 2,3 또는 4이고,y is 2,3 or 4, q는 0 또는 1이고,q is 0 or 1, t는 1,2,3 또는 4이고,t is 1,2,3 or 4, x는 수소, 카르복실 또는 카르바모일기이다.x is hydrogen, carboxyl or carbamoyl group. 제1항에 있어서, R가인 화합물.The compound of claim 1 wherein R is Phosphorus compounds. 제1항에 있어서, R가인 화합물.The compound of claim 1 wherein R is Phosphorus compounds. 제1항에 있어서, R가인 화합물.The compound of claim 1 wherein R is Phosphorus compounds. 제1항에 있어서, R가인 화합물.The compound of claim 1 wherein R is Phosphorus compounds. 제1항에 있어서, R가인 화합물.The compound of claim 1 wherein R is Phosphorus compounds. 제1항에 있어서, R가인 화합물.The compound of claim 1 wherein R is Phosphorus compounds. 제2항에 있어서, A1이 단일 결합인 화합물.The compound of claim 2, wherein A 1 is a single bond. 제2항에 있어서, A2가 -NH-인 화합물.The compound of claim 2, wherein A 2 is —NH—. 제2항에 있어서, A6가 단일 결합인 화합물.The compound of claim 2, wherein A 6 is a single bond. 제1항에 있어서, R1이인 화합물.The compound of claim 1, wherein R 1 is Phosphorus compounds. 제1항에 있어서, R2및 R3가 각각 수소인 화합물.The compound of claim 1, wherein R 2 and R 3 are each hydrogen. 제1항에 있어서, R1이Rg는 2-아미노-4-티아졸릴이고, Ri는 메틸, 에틸, 카르복시메틸, 1-카르복시-1-메틸에틸, 1-카르복시-1-에틸 또는(여기서 s는 1,2 또는 3임)인 화합물.The compound of claim 1, wherein R 1 is R g is 2-amino-4-thiazolyl, R i is methyl, ethyl, carboxymethyl, 1-carboxy-1-methylethyl, 1-carboxy-1-ethyl or Wherein s is 1,2 or 3; 제1항에 있어서, R1이Rg는 2-아미노-4-티아졸릴이고, Ri는 카르복시메틸, 1-카르복시-1-메틸에틸, 1-카르복시-1-에틸 또는(여기서 s는 1,2 또는 3임)인 화합물.The compound of claim 1, wherein R 1 is R g is 2-amino-4-thiazolyl, R i is carboxymethyl, 1-carboxy-1-methylethyl, 1-carboxy-1-ethyl or Wherein s is 1,2 or 3; 제2항에 있어서, R1이Rg는 2-아미노-4-티아졸릴이고, Ri는 메틸, 에틸, 카르복시메틸, 1-카르복시-1-메틸에틸, 1-카르복시-1-에틸 또는(여기서 s는 1,2 또는 3임)인 화합물.The compound of claim 2, wherein R 1 is R g is 2-amino-4-thiazolyl, R i is methyl, ethyl, carboxymethyl, 1-carboxy-1-methylethyl, 1-carboxy-1-ethyl or Wherein s is 1,2 or 3; 제2항에 있어서, R1이Rg는 2-아미노-4-티아졸릴이고, Ri는 카르복시메틸, 1-카르복시-1-메틸에틸, 1-카르복시-1-에틸 또는(여기서 s는 1,2 또는 3임)인 화합물.The compound of claim 2, wherein R 1 is R g is 2-amino-4-thiazolyl, R i is carboxymethyl, 1-carboxy-1-methylethyl, 1-carboxy-1-ethyl or Wherein s is 1,2 or 3; 제11항에 있어서, R이Rg는 2-아미노-4-티아졸릴이고, Ri는 메틸, 에틸, 카르복시메틸, 1-카르복시-1-메틸에틸, 1-카르복시-1-에틸 또는(여기서 s는 1,2 또는 3임)인 화합물.12. The compound of claim 11 wherein R is R g is 2-amino-4-thiazolyl, R i is methyl, ethyl, carboxymethyl, 1-carboxy-1-methylethyl, 1-carboxy-1-ethyl or Wherein s is 1,2 or 3; 제11항에 있어서, R1이Rg는 2-아미노-4-티아졸릴이고, Ri는 카르복시메틸 또는 1-카르복시-1-메틸에틸인 화합물.The compound of claim 11, wherein R 1 is R g is 2-amino-4-thiazolyl and R i is carboxymethyl or 1-carboxy-1-methylethyl. 제11항에 있어서, R2및 R3가 각각 수소인 화합물.The compound of claim 11, wherein R 2 and R 3 are each hydrogen. 제1항에 있어서, [3S(A)[-2-[[[1-(2-아미노-4-티아졸릴)-2-[[1-[[[[3-[[[[3-[[(1,4-디히드로-5-히드록시-4-옥소-2-피리디닐)카르보닐]아미노]-2-옥소-1-이미다졸리디닐]술포닐]아미노]카르보닐]-2-옥소-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]-2-메틸프로판산 또는 그의 제약상 허용되는 염.The compound of claim 1, wherein [3S (A) [-2-[[[1- (2-amino-4-thiazolyl) -2-[[1-[[[[3-[[[[3- [ [(1,4-dihydro-5-hydroxy-4-oxo-2-pyridinyl) carbonyl] amino] -2-oxo-1-imidazolidinyl] sulfonyl] amino] carbonyl] -2 Oxo-3-azetidinyl] amino] -2-oxoethylidene] amino] oxy] -2-methylpropanoic acid or a pharmaceutically acceptable salt thereof. 제1항에 있어서, [3S(Z)]-2-[[[1-(2-아미노-4-티아졸릴)-2-[[1-[[[[2-[[(1,4-디히드로-5-히드록시-4-옥소-2-피리디닐)카르보닐]]히드라지노]술포닐]아미노]카르보닐]-2-옥소-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]-2-메틸프로판산 또는 그의 제약상 허용되는 염.The compound of claim 1, wherein [3S (Z)]-2-[[[1- (2-amino-4-thiazolyl) -2-[[1-[[[[2-[[(1,4- Dihydro-5-hydroxy-4-oxo-2-pyridinyl) carbonyl]] hydrazino] sulfonyl] amino] carbonyl] -2-oxo-3-azetidinyl] amino] -2-oxo Thilidene] amino] oxy] -2-methylpropanoic acid or a pharmaceutically acceptable salt thereof. 제1항에 있어서, [3S(Z)]-2-[[[1-(2-아미노-4-티아졸릴)-2-[[1-[[[[3-[[(1,4-디히드로-5-히드록시-4-옥소-2-피리디닐)카르보닐]]아미노]-2-옥소-1-이미자졸리디닐]술포닐]아미노]-카르보닐]-2-옥소-3-아제티디닐]아미노]옥시]-2-메틸프로판산 또는 그의 제약상 허용되는 염.The compound of claim 1, wherein [3S (Z)]-2-[[[1- (2-amino-4-thiazolyl) -2-[[1-[[[[3-[[(1,4- Dihydro-5-hydroxy-4-oxo-2-pyridinyl) carbonyl]] amino] -2-oxo-1-imizazolidinyl] sulfonyl] amino] -carbonyl] -2-oxo-3- Azetidinyl] amino] oxy] -2-methylpropanoic acid or a pharmaceutically acceptable salt thereof. 제1항에 있어서, [3S(Z)]-2-[[[1-(2-아미노-4-티아졸릴)-2-[[1-[[[[[1,4-디히드로-5-히드록시-4-옥소-2-피리디닐)메틸]아미노]카르보닐]-2-옥소-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]-2-메틸프로판산 또는 그의 제약상 허용되는 염.The compound of claim 1, wherein [3S (Z)]-2-[[[1- (2-amino-4-thiazolyl) -2-[[1-[[[[[1,4-dihydro-5] -Hydroxy-4-oxo-2-pyridinyl) methyl] amino] carbonyl] -2-oxo-3-azetidinyl] amino] -2-oxoethylidene] amino] oxy] -2-methylpropane Acids or pharmaceutically acceptable salts thereof. 제1항에 있어서, [3S(Z)]-2-[[[1-(2-아미노-4-티아졸릴)-2-[[1-[[[[2-[[[2-[(1,4-디히드로-5-히드록시-4-옥소-2-피리디닐)카르보닐]]히드라지노]술포닐]아미노]카르보닐]-2-옥소-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]-2-메틸프로판산 또는 그의 제약상 허용되는 염.The compound of claim 1, wherein [3S (Z)]-2-[[[1- (2-amino-4-thiazolyl) -2-[[1-[[[[2-[[[2-[( 1,4-dihydro-5-hydroxy-4-oxo-2-pyridinyl) carbonyl]] hydrazino] sulfonyl] amino] carbonyl] -2-oxo-3-azetidinyl] amino]- 2-oxoethylidene] amino] oxy] -2-methylpropanoic acid or a pharmaceutically acceptable salt thereof. 제1항에 있어서, [3S-(3α(Z),4β]]-2-[[[1-(2-아미노-4-티아졸릴)-2-[[1-[[[[2-[[(1,4-디히드로-5-히드록시-4-옥소-2-피리디닐)카르보닐]]히드라지노]술포닐]아미노]카르보닐]-4-메틸-2-옥소-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]-2-메틸프로판산 또는 그의 제약상 허용되는 염.The compound of claim 1, wherein [3S- (3α (Z), 4β]]-2-[[[1- (2-amino-4-thiazolyl) -2-[[1-[[[[2- [ [(1,4-dihydro-5-hydroxy-4-oxo-2-pyridinyl) carbonyl]] hydrazino] sulfonyl] amino] carbonyl] -4-methyl-2-oxo-3-ase Thidinyl] amino] -2-oxoethylidene] amino] oxy] -2-methylpropanoic acid or a pharmaceutically acceptable salt thereof. 제1항에 있어서, [3S(Z)]-1-[[[1-(2-아미노-4-티아졸릴)-2-[[1-[[[[3-[[(1,4-디히드로-5-히드록시-4-옥소-2-피리디닐)카르보닐]]아미노]카르보닐]-2-옥소-3-아미다졸리디닐]술포닐]아미노]카르보닐]-2-옥소-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]시클로펜탄카르복실산 또는 그의 제약상 허용되는 염.The compound of claim 1, wherein [3S (Z)]-1-[[[1- (2-amino-4-thiazolyl) -2-[[1-[[[[3-[[(1,4- Dihydro-5-hydroxy-4-oxo-2-pyridinyl) carbonyl]] amino] carbonyl] -2-oxo-3-amidazolidinyl] sulfonyl] amino] carbonyl] -2-oxo -3-azetidinyl] amino] -2-oxoethylidene] amino] oxy] cyclopentanecarboxylic acid or a pharmaceutically acceptable salt thereof. (1) 하기 구조식(1) the following structural formula 의 화합물을 R1-카르복실산에서 유도된 R1이 아실기로 아실화거나 또는The compound of R 1 - R 1 groups are derived from a carboxylic acid acyl, or acylated 의 화합물에 -CO-NH-SO2R 활성기를 도입함을 특징으로 하는 제1항 내지 제26항에 의한 화합물의 제조방법.27. A process for the preparation of a compound according to claims 1 to 26, wherein a -CO-NH-SO 2 R activating group is introduced into the compound. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019860008067A 1985-09-26 1986-09-26 2-oxo-1-(((substituted sulfonyl) amino) carbonyl) azetidines KR900001013B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78047985A 1985-09-26 1985-09-26
US780479 1985-09-26

Publications (2)

Publication Number Publication Date
KR870003101A true KR870003101A (en) 1987-04-15
KR900001013B1 KR900001013B1 (en) 1990-02-24

Family

ID=25119699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860008067A KR900001013B1 (en) 1985-09-26 1986-09-26 2-oxo-1-(((substituted sulfonyl) amino) carbonyl) azetidines

Country Status (31)

Country Link
JP (1) JPS6284082A (en)
KR (1) KR900001013B1 (en)
CN (1) CN86106980A (en)
AT (1) ATA257986A (en)
AU (1) AU600912B2 (en)
BE (1) BE905502A (en)
CA (1) CA1308719C (en)
CH (1) CH670828A5 (en)
DD (1) DD250121A5 (en)
DE (1) DE3632876A1 (en)
DK (1) DK460386A (en)
EG (1) EG18314A (en)
ES (1) ES2001995A6 (en)
FI (1) FI863890A (en)
FR (1) FR2587700B1 (en)
GB (1) GB2181130B (en)
GR (1) GR862449B (en)
HU (1) HU198044B (en)
IE (1) IE59686B1 (en)
IL (1) IL80160A (en)
IT (1) IT1214533B (en)
LU (1) LU86611A1 (en)
NL (1) NL8602446A (en)
NO (1) NO863837L (en)
NZ (1) NZ217704A (en)
PH (1) PH23315A (en)
PL (1) PL151546B1 (en)
PT (1) PT83440B (en)
SE (1) SE8604089L (en)
YU (1) YU46177B (en)
ZA (1) ZA867373B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502660A (en) * 1986-05-23 1989-09-14 ジ・アップジョン・カンパニー N-1 substituted sulfonylaminocarbonyl, C-4 substituted monobactams
AU602067B2 (en) * 1987-02-11 1990-09-27 Upjohn Company, The Novel n-1 substituted beta-lactams as antibiotics
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
EP0357604A1 (en) * 1987-02-27 1990-03-14 The Upjohn Company Antibiotic beta-lactams containing a pyridone carboxylic acid or acid derivative
CA1317298C (en) * 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
US4762922A (en) * 1987-07-01 1988-08-09 Squibb Corporation 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US4772693A (en) * 1987-07-01 1988-09-20 E. R. Squibb & Sons, Inc. 2-oxo-1-((Substituted sulfonyl)amino)-carbonyl)azetidines
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
JPH02504272A (en) * 1987-07-22 1990-12-06 ジ・アップジョン・カンパニー Therapeutically useful beta-lactams
US4777252A (en) * 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US4889930A (en) * 1987-12-21 1989-12-26 E. R. Squibb & Sons, Inc. Process for making 2-oxo-1-((substituted sulfonyl)amino)carbonzyl)azetidines and intermediates used therein
US4871841A (en) * 1987-12-23 1989-10-03 E. R. Squibb & Sons, Inc. 2-Oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
EP0336667A3 (en) * 1988-04-04 1991-04-10 E.R. Squibb & Sons, Inc. [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoethoxy]imino]acetyl]-amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate
US4959470A (en) * 1988-08-17 1990-09-25 E. R. Squibb & Sons, Inc. 2-oxo-[[(substituted sulfonyl)-amino]carbonyl]-azetidines
ATE180474T1 (en) * 1992-12-23 1999-06-15 Novartis Ag IMIDAZOLE DERIVATIVES AND THEIR USE AS AGROCHEMICAL AGENTS
DE69405535T2 (en) * 1994-03-11 1998-04-02 Agfa Gevaert Nv Photographic material containing a new type of hydrazide
EP2308562B1 (en) * 2003-12-25 2015-02-25 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (en) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors
PE20141361A1 (en) 2011-11-15 2014-10-13 Takeda Pharmaceutical AROMATIC DIHYDROXY HETEROCYCLIC COMPOUND
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
CN106986820B (en) * 2017-02-24 2019-05-21 浙江工商大学 The preparation method and purposes of multi-functional pyridone ketone derivatives and its hydrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199981A (en) * 1981-04-09 1985-08-16 Squibb & Sons Inc 2-oxo-1-(((substituted sulphonyl)amino)carbonyl)azetidines
CA1272726C (en) * 1982-01-04 1990-08-14 2-oxo-1-(aminocarbonylaminosulfonyl- aminocarbonyl)azetidines
US4939253A (en) * 1982-08-04 1990-07-03 E. R. Squibb & Sons, Inc. 2-oxoazetidin-1-yloxy acetic acids and analogs
US4801705A (en) * 1986-06-23 1989-01-31 E. R. Squibb & Sons, Inc. 2-oxo-1-(((substituted sulfonyl)amino)-carbonyl)azetidines

Also Published As

Publication number Publication date
DK460386A (en) 1987-03-27
DE3632876A1 (en) 1987-04-02
CA1308719C (en) 1992-10-13
FR2587700B1 (en) 1988-09-16
GB8623151D0 (en) 1986-10-29
BE905502A (en) 1987-01-16
PL261575A1 (en) 1988-07-21
ZA867373B (en) 1987-05-27
FI863890A0 (en) 1986-09-26
GB2181130A (en) 1987-04-15
IL80160A (en) 1991-04-15
JPS6284082A (en) 1987-04-17
SE8604089L (en) 1987-03-27
HUT44535A (en) 1988-03-28
ATA257986A (en) 1994-07-15
NL8602446A (en) 1987-04-16
DK460386D0 (en) 1986-09-26
YU165986A (en) 1988-06-30
NZ217704A (en) 1989-02-24
DD250121A5 (en) 1987-09-30
NO863837L (en) 1987-03-27
PL151546B1 (en) 1990-09-28
GR862449B (en) 1987-01-27
PT83440B (en) 1989-05-12
IT8621834A0 (en) 1986-09-26
AU6315686A (en) 1987-04-02
CH670828A5 (en) 1989-07-14
PT83440A (en) 1986-10-01
KR900001013B1 (en) 1990-02-24
IE862547L (en) 1987-03-26
IE59686B1 (en) 1994-03-23
CN86106980A (en) 1987-04-08
ES2001995A6 (en) 1988-07-01
NO863837D0 (en) 1986-09-26
EG18314A (en) 1993-02-28
FI863890A (en) 1987-03-27
PH23315A (en) 1989-07-14
AU600912B2 (en) 1990-08-30
IL80160A0 (en) 1986-12-31
SE8604089D0 (en) 1986-09-26
FR2587700A1 (en) 1987-03-27
YU46177B (en) 1993-05-28
HU198044B (en) 1989-07-28
LU86611A1 (en) 1987-04-02
IT1214533B (en) 1990-01-18
GB2181130B (en) 1989-09-20

Similar Documents

Publication Publication Date Title
KR870003101A (en) 2-oxo-1-[[(substituted sulfonyl) amino] carbonyl] azetidine
AU621865B2 (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
FI81085C (en) FRUIT PROCEDURE FOR FRAMSTAELLNING AV NYA, PHARMACEUTICAL ACTIVATED 1-SULFO-2-OXOAZETIDINDERIVAT.
KR880007460A (en) 3-hetero-substituted-N-benzyl-indole
CA2464358C (en) Alkyl ether derivatives or their salts
KR880002814A (en) Aryloxycarboxylic Acid Derivatives, Method of Preparation and Use thereof
LU90011I2 (en) Remifentanil optionally in the form of a pharmaceutically acceptable acid addition salt including remifentanil hydrochloride
KR840005814A (en) Method for preparing an azetidine compound
PT1004578E (en) HYDROXAMIDE DERIVATIVES OF 5-OXO-PYRROLIDINE-2-CARBOXYLIC ACID
PT747374E (en) BENZOPIRANOS SUBSTITUTED WITH SULFONAMID ACTIVATORS OF POTASSIO CHANNELS
KR900009635A (en) The novel compound
IL103564A (en) Aromatic amidine derivatives and anticoagulation pharmaceutical compositions containing them
DE19575041I2 (en) Substituted acyl derivatives of 1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-3-isoquinoline carboxylic acid
JP2006518728A5 (en)
RU96111018A (en) AMIDA THERAPEUTIC TREATMENT
EA199900332A1 (en) β-Sulfonyl Hydroxamic Acids As Inhibitors of Matrix Metal Proteins
WO1999002146A8 (en) Amino acid derivatives
EA200200774A1 (en) NEW CONNECTIONS, HAVING HYPOLIPIDEMIC, HYPOCHOLESTERYNAMIC ACTIVITY, METHOD OF THEIR PREPARATION AND CONTAINING THEIR COMPOSITION
RU96113098A (en) 5,6-DIHYDROPYRON DERIVATIVES AS A PROTEASIS INHIBITOR AND ANTI-VIRUS MEANS
FI903939A0 (en) BENZOPYRANFOERENINGAR, FOERFARANDEN FOER DERAS FRAMSTAELLNING OCH PHARMACEUTISKA KOMPOSITIONER.
EP2215084A2 (en) Therapeutic substituted lactams
ZA200106514B (en) Heterocyclic compounds intermediates thereof and elastase inhibitors.
HU9402746D0 (en) Azole compounds, pharmaceutical compositions containing them and process for producing formers
KR880000423A (en) 2-oxo-1-[[(substituted sulfonyl) amino] -carbonyl] azetidine
KR920009827A (en) Heteroaroyl Derivatives of Monocyclic β-lactam Antibiotics

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19931208

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee